infect
main
caus
treatmentrel
mortal
patient
hematolog
therefor
earli
diagnosi
treatment
infect
well
infect
prevent
essenti
improv
prognosi
immun
compromis
patient
patient
neutropen
fever
nf
focu
bacteri
fungal
infect
among
virus
herpesvirida
maintain
latenc
reactiv
immun
suppress
caus
anticanc
chemotherapi
hematopoiet
cell
transplant
hct
consid
major
pathogen
howev
caus
pathogen
identifi
patient
may
respiratori
virus
rv
viral
cultur
antigen
detect
method
use
diagnosi
viral
infect
convent
method
low
sensit
detect
rhinoviru
enteroviru
common
caus
communityacquir
respiratori
viral
infect
rvi
rvi
identifi
immun
compromis
children
respiratori
symptom
also
previou
studi
restrict
report
rvi
due
respiratori
syncyti
viru
rsv
parainfluenza
viru
influenza
viru
adenoviru
could
diagnos
convent
polymeras
chain
reaction
pcr
test
exhibit
improv
sensit
specif
diagnosi
rvi
immun
compromis
patient
compar
convent
method
introduc
use
extend
sinc
recent
studi
use
pcr
test
identifi
rvi
children
nf
cancer
complain
respiratori
rsv
influenza
viru
frequent
caus
rvi
era
convent
wherea
rhinoviru
frequent
caus
era
pcr
spite
epidemiolog
chang
accompani
introduct
pcr
test
report
clinic
characterist
prognosi
rvi
immun
compromis
children
adolesc
use
pcr
test
lack
accordingli
guidelin
applic
pcr
test
diagnosi
proper
manag
rvi
immun
compromis
children
adolesc
establish
studi
perform
evalu
clinic
characterist
outcom
rvi
diagnos
multiplex
pcr
test
rv
establish
strategi
perform
pcr
test
children
adolesc
hematolog
malign
compris
major
portion
immun
compromis
children
adolesc
children
adolesc
year
age
underli
hematolog
malign
treat
depart
pediatr
seoul
st
mari
hospit
colleg
medicin
cathol
univers
korea
elig
studi
among
complain
respiratori
symptom
cough
rhinorrhea
sputum
sore
throat
dyspnea
without
fever
multiplex
pcr
test
rv
perform
decemb
novemb
enrol
patient
respiratori
symptom
develop
month
complet
anticanc
chemotherapi
year
hct
exclud
patient
hematolog
malign
newli
diagnos
anticanc
chemotherapi
administ
prior
develop
respiratori
ill
also
exclud
patient
rv
identifi
identifi
categor
group
ii
respect
medic
record
enrol
patient
review
retrospect
clinic
laboratori
characterist
compar
group
patient
group
subdivid
upper
respiratori
tract
infect
uri
lower
respiratori
tract
infect
lri
clinic
laboratori
characterist
also
compar
two
subgroup
studi
approv
institut
review
board
seoul
st
mari
hospit
waiver
inform
consent
approv
number
nasopharyng
swab
collect
patient
complain
respiratori
symptom
sampl
sent
depart
laboratori
medicin
multiplex
pcr
test
rv
perform
use
commerci
avail
kit
rv
realtim
pcr
kit
lg
life
scienc
ltd
seoul
republ
korea
pcr
kit
test
influenza
b
virus
parainfluenza
viru
rhinoviru
rsv
human
metapneumoviru
hmpv
adenoviru
coronaviru
human
bocaviru
chest
xray
routin
perform
patient
respiratori
symptom
chest
comput
tomographi
perform
base
attend
physician
clinic
decis
oseltamivir
administ
patient
diagnos
influenza
base
attend
physician
decis
oral
ribavirin
intraven
immunoglobulin
ivig
administ
febril
patient
receiv
empir
antibiot
therapi
episod
respiratori
ill
occur
week
previou
episod
consid
separ
episod
occur
separ
admiss
patient
respiratori
complaint
two
episod
uri
diagnos
patient
respiratori
symptom
accompani
hypoxemia
abnorm
find
chest
imag
studi
lri
diagnos
abnorm
find
observ
chest
imag
studi
due
difficulti
associ
obtain
sputum
sampl
perform
bronchoscopi
children
adolesc
underli
hematolog
malign
prone
bleed
nasopharyng
sampl
use
diagnos
lri
although
lower
respiratori
sampl
prefer
communityacquir
respiratori
ill
defin
respiratori
symptom
develop
within
day
admiss
hospitalacquir
respiratori
ill
defin
respiratori
symptom
develop
day
admiss
neutropenia
defin
absolut
neutrophil
count
steroid
use
defin
type
glucocorticoid
equival
mgkgday
maximum
mgday
prednisolon
administ
longer
day
within
month
prior
develop
respiratori
ill
oxygen
therapi
mechan
ventil
care
intens
care
unit
admiss
death
occur
within
month
develop
respiratori
ill
consid
complic
coinfect
defin
type
nonvir
infect
identifi
time
patient
complaint
respiratori
symptom
mortal
within
month
develop
respiratori
ill
determin
mortal
due
rvi
defin
patient
die
persist
respiratori
symptom
sign
caus
death
identifi
categor
continu
factor
compar
use
chisquar
mannwhitney
test
respect
comparison
patient
group
multivari
analys
identifi
independ
factor
rvi
lri
perform
signific
factor
univari
analysi
use
binari
logist
regress
analysi
ibm
spss
statist
window
version
ibm
corp
armonk
ny
usa
use
statist
analys
statist
signific
defin
pvalu
rate
differ
underli
hematolog
malign
administ
chemotherapi
preced
respiratori
ill
significantli
differ
two
group
significantli
patient
group
ii
present
hospitalacquir
respiratori
ill
accompani
neutropenia
group
tabl
patient
overal
complain
fever
cough
howev
group
complain
rhinorrhea
p
sputum
frequent
group
ii
multivari
analysi
rhinorrhea
sputum
communityacquir
respiratori
ill
signific
factor
diagnosi
rvi
tabl
significantli
complic
occur
patient
group
ii
compar
group
tabl
mortal
higher
group
ii
group
howev
differ
statist
signific
patient
group
lri
like
uncontrol
underli
malign
receiv
reinduct
palli
chemotherapi
uri
tabl
among
respiratori
symptom
sputum
dyspnea
frequent
accompani
lri
patient
lri
experienc
coinfect
uri
among
five
patient
lri
coinfect
four
experienc
invas
pulmonari
aspergillosi
two
concomit
rsv
infect
anoth
concomit
adenoviru
infect
hmpv
infect
experienc
c
difficil
infect
concomit
parainfluenza
viru
infect
two
patient
uri
coinfect
experienc
chickenpox
concomit
rhinoviru
infect
epidermidi
bacteremia
concomit
rsv
infect
respect
rate
rhinoviru
infect
significantli
higher
patient
uri
lri
viral
infect
show
signific
associ
lri
tabl
independ
risk
factor
lri
multivari
analysi
data
shown
patient
parainfluenza
viru
infect
five
receiv
ribavirin
treatment
one
also
receiv
ivig
patient
rsv
infect
eight
receiv
ribavirin
treatment
three
also
receiv
ivig
patient
lri
like
receiv
oxygen
therapi
p
uri
mortal
higher
patient
lri
compar
uri
although
differ
statist
signific
fatal
group
caus
uncontrol
underli
malign
studi
clinic
characterist
outcom
rvi
investig
children
adolesc
hematolog
malign
rvi
diagnos
half
enrol
patient
consist
result
previou
studi
use
pcr
test
diagnos
rhinoviru
rather
rsv
parainfluenza
viru
frequent
caus
rvi
consist
result
recent
studi
use
pcr
rvi
investig
consid
immun
compromis
patient
complain
communityacquir
respiratori
symptom
prefer
rhinorrhea
sputum
predomin
cough
consid
earli
termin
empir
antibiot
therapi
led
favor
outcom
children
adolesc
nf
rvi
recent
report
santolaya
et
earli
diagnosi
rvi
pcr
test
patient
help
avoid
unnecessari
antibiot
use
neutropenia
identifi
patient
diagnos
rvi
studi
therefor
diagnosi
rvi
restrict
patient
nf
matter
fact
patient
group
ii
presenc
rv
identifi
like
neutropenia
hospitalacquir
sever
respiratori
ill
infect
nonvir
pathogen
suggest
patient
group
ii
underw
aggress
anticanc
chemotherapi
sever
immunosuppress
hospit
longer
period
compar
patient
group
thu
pulmonari
edema
aris
hyperhydr
anticanc
chemotherapi
pulmonari
hemorrhag
due
thrombocytopenia
bacteri
fungal
pneumonia
could
lead
respiratori
symptom
patient
neg
pcr
result
patient
nf
hospitalacquir
respiratori
ill
may
suggest
presenc
sever
infect
treatmentrel
complic
although
communityonset
respiratori
ill
significantli
associ
diagnosi
rvi
studi
rvi
case
hospitalacquir
infect
sever
studi
includ
present
studi
outbreak
rsv
parainfluenza
viru
infect
report
outpati
depart
well
inpati
ward
also
experienc
outbreak
rsv
infect
seven
patient
one
month
close
hematolog
ward
therefor
multiplex
pcr
test
rv
encourag
even
hospit
patient
complain
rhinorrhea
sputum
particularli
patient
rvi
hospit
ward
rvi
epidem
commun
time
applic
pcr
test
lead
earli
diagnosi
rvi
hospit
patient
subsequ
decreas
rvi
transmiss
within
hospit
environ
recent
studi
rvi
immun
compromis
children
show
low
mortal
due
rvi
fortun
death
due
rvi
studi
favor
outcom
may
attribut
grow
concern
rvi
physician
increas
diagnost
rate
especi
mild
rvi
case
use
pcr
test
improv
support
care
immun
compromis
patient
ribavirinbas
antivir
therapi
reduc
progress
uri
lri
mortal
rsvinfect
hct
recipi
howev
recommend
patient
hematolog
malign
receiv
hct
effect
parainfluenza
viru
infect
studi
patient
diagnos
rsv
infect
receiv
ribavirinbas
antivir
therapi
regardless
receiv
hct
none
die
due
rsv
infect
howev
efficaci
ribavirinbas
therapi
evalu
antivir
therapi
perform
studi
reli
current
establish
criteria
risk
factor
mortal
due
rvi
could
determin
studi
death
attribut
rvi
previou
studi
univers
report
lri
associ
increas
even
rhinoviru
infect
caus
milder
respiratori
ill
compar
rsv
parainfluenza
viru
influenza
viru
mortal
significantli
higher
patient
lri
therefor
earli
detect
patient
risk
progress
lri
earli
applic
proper
manag
lri
necessari
improv
outcom
rvi
immun
compromis
patient
low
absolut
lymphocyt
neutrophil
monocyt
count
relaps
underli
malign
unrel
mismatch
allogeneichct
recent
steroid
use
oxygen
need
coinfect
risk
factor
lri
risk
factor
repres
sever
immun
suppress
infect
accordingli
immunodefici
score
system
predict
outcom
determin
administr
antivir
therapi
appli
rsvinfect
hct
uncontrol
state
underli
hematolog
malign
presenc
coinfect
significantli
associ
develop
lri
studi
underscor
import
host
overal
immun
statu
outcom
rvi
result
multiplex
pcr
test
rv
perform
preferenti
patient
complain
rhinorrhea
sputum
relaps
refractori
underli
hematolog
malign
coinfect
sever
cytopenia
consid
lri
case
progress
uri
studi
earli
applic
multiplex
pcr
test
uri
period
emphas
studi
limit
includ
bias
aris
retrospect
studi
design
number
enrol
patient
may
appropri
lack
control
group
includ
patient
without
respiratori
symptom
although
lower
respiratori
sampl
sputum
bronchial
wash
bronchoalveolar
lavag
fluid
prefer
sampl
lri
diagnosi
upper
respiratori
sampl
use
studi
assur
improv
diagnosi
lri
abnorm
find
chest
imag
studi
mandatori
lri
diagnosi
studi
howev
lower
respiratori
sampl
could
reveal
clearer
pathogen
profil
season
distribut
epidem
rvi
immun
compromis
patient
correl
observ
studi
period
epidem
rsv
influenza
viru
infect
commun
promin
korea
compar
previou
year
inclus
rsv
influenza
viru
infect
episod
may
modifi
outcom
rvi
studi
futur
studi
analyz
data
gather
sever
year
includ
case
rvi
caus
varieti
rv
multiplex
pcr
test
rv
routin
perform
children
adolesc
respiratori
symptom
hospit
studi
period
hardli
perform
outpati
clinic
therefor
children
adolesc
mild
respiratori
symptom
uri
could
includ
studi
outcom
rvi
immun
compromis
children
adolesc
may
favor
inclus
mild
rvi
case
consid
confirm
rvi
diagnosi
half
immun
compromis
children
adolesc
respiratori
symptom
studi
introduct
multiplex
pcr
test
rv
detect
popul
encourag
especi
patient
complain
rhinorrhea
sputum
promin
cough
moreov
pcr
test
address
patient
sever
immun
suppress
eg
relaps
refractori
underli
malign
coinfect
prone
sever
rvirel
outcom
addit
infect
control
strategi
prevent
rvi
transmiss
within
hospit
environ
emphas
consid
current
scenario
effect
antivir
therapi
establish
rvi
case
thu
earli
rvi
detect
pcr
test
may
open
window
opportun
earli
intervent
infect
control
